Gossamer Bio (GOSS) Files First NDA for Seralutinib, Shares Reflect Market Skepticism
· gurufocus.com
On September 23, 2026, Gossamer Bio Inc (NASDAQ: GOSS) announced the official filing of its first New Drug Application (NDA) with the U.S. FDA for seralutinib,
On September 23, 2026, Gossamer Bio Inc (NASDAQ: GOSS) announced the official filing of its first New Drug Application (NDA) with the U.S. FDA for seralutinib, ...